• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Pacific Biosciences Reaches Our Price Target: Now What?

Let's check out the charts and technical indicators.
By BRUCE KAMICH
Jan 13, 2021 | 12:19 PM EST
Stocks quotes in this article: PACB

"This is another great stock," Jim Cramer told viewers of the Lightning Round segment of Mad Money Tuesday evening when asked about Pacific Biosciences of California Inc. (PACB) . The company provides sophisticated genomic analysis systems and according to the company's website they have developed a Single Molecule, Real-Time Sequencing technology.

This is above my pay grade so let's check out the charts and technical indicators. 

We looked at the charts of PACB on Dec. 9 and wrote that, "Maybe in 2021 PACB goes on to rally to $39 but in the here and now when a stock is trading at three times its 200-day moving average line it is a clear message that prices are overbought/extended. Buyer beware!"

In the daily Japanese candlestick chart of PACB, below, we can see that the shares corrected modestly after our Dec. 9 review and subsequently rallied to the $39 price target. Now what?

This chart shows that prices are above the rising 50-day moving average line and trade at more than three times the level of the rising 200-day moving average line. PACB is more extended (overbought) than back in early December.

Trading volume has been active the past four months and could be telling us that older longs are selling to newer buyers or a transfer from strong hands to weaker hands. The On-Balance-Volume (OBV) line is pointed up and tells us that on the surface buyers are still more aggressive.

The Moving Average Convergence Divergence (MACD) oscillator is pointed up but could cross to the downside soon for a take profit sell signal. 

 
In the weekly Japanese candlestick chart of PACB, below, we can see that prices are up more than 10-fold from their 2020 lows. Fantastic returns! PACB is above the rising 40-week moving average line but extended.
 
The weekly OBV line is pointed up and the MACD oscillator is bullish.  
 
 
 
In this daily Point and Figure chart of PACB, below, we can see a potential price target of $48. We can also see that a decline below $32 is likely to weaken the picture. 
 
 
 
Bottom-line strategy: What should you do when a stock you own is trading at 3-1/2-times the level of the 200-day moving average line? The late Joseph Granville would probably tell you to take profits.
 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited

TAGS: Investing | Stocks | Technical Analysis | Biotechnology | Healthcare | Life Sciences | Mad Money

More from Stocks

Cord-Cutting FuboTV and Advertising Platform PubMatic Are Not Buys Here

Bruce Kamich
Jan 21, 2021 2:59 PM EST

Our look at the stocks of both FUBO and PUBM.

Hyliion Should Keep Truckin'

Timothy Collins
Jan 21, 2021 2:49 PM EST

I see a good trade down the road in this commercial fleet alternative-power truck name.

Jim Cramer: You Just Won Powerball, Now What?

Jim Cramer
Jan 21, 2021 2:24 PM EST

Remember, you only need to get rich once.

Aim High With This Defensive Dividend Stock

Bob Ciura
Jan 21, 2021 1:40 PM EST

Lockheed Martin is a classic defense stock that also gives investors an offensive position.

A Day for Resets

James "Rev Shark" DePorre
Jan 21, 2021 1:08 PM EST

I'm more inclined to do strategic buying in this sort of market action rather than more aggressive selling.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:16 AM EST CHRIS VERSACE

    Worst Stocks to Buy for the Biden Presidency

    Biden's take on the minimum wage, likely moves on ...
  • 08:35 AM EST GARY BERMAN

    Thursday Morning Fibocall for 1/21/2021

    SPX (Long-Term View) The 1/20/21 NEW high @ 3859...
  • 11:38 AM EST CHRIS VERSACE

    Best Stocks to Buy for the Biden Presidency

    President-elect Biden's massive stimulus plan, int...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login